FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental and clinical medicine. At least 50–58 hours before the surgical operation, a mononuclear fraction of bone marrow cells is recovered from the bone marrow of the donor. Then total RNA is extracted from obtained fraction and introduced to experimental animal – rat intraperitoneally or intravenously in dose 50–60 mcg/100 g of experimental animal weight twice, at first 44–52 hours prior to operation, and then in 3–4 hours after it.
EFFECT: method enables reducing the length of treatment or prevention of acute hepatic impairment with simultaneous increase of efficiency, prevention of lethal outcome by means of early provision of the required level of activation of mitotic and proliferative cell activity in the operated patient.
4 cl, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF ACUTE LIVER FAILURE | 2020 |
|
RU2744846C1 |
| METHOD OF TREATING HEPATIC FAILURE | 2017 |
|
RU2655528C1 |
| METHOD OF CORRECTION OF HEPATIC INSUFFICIENCY IN THE EXPERIMENT | 2017 |
|
RU2650209C1 |
| USE OF TOTAL RIBONUCLEIC ACID (RNA) FROM MULTIPOTENT MESENCHYMAL STROMAL CELLS OF THE MAMMAL'S BONE MARROW AS METHOD FOR CORRECTING LIVER FAILURE | 2017 |
|
RU2655761C1 |
| METHOD OF CHRONIC HEPATIC FAILURE CORRECTION | 2020 |
|
RU2739996C1 |
| METHOD AND TRANSPLANT FOR TREATMENT OF LIVER FAILURE | 2010 |
|
RU2425648C1 |
| METHOD AND TRANSPLANT FOR TREATMENT OF LIVER FAILURE | 2010 |
|
RU2425645C1 |
| METHOD AND TRANSPLANT FOR TREATMENT OF LIVER FAILURE | 2010 |
|
RU2425646C1 |
| METHOD AND TRANSPLANT FOR TREATMENT OF LIVER FAILURE | 2010 |
|
RU2425647C1 |
| METHOD OF THE TREATMENT OF LIVER FIBROSIS BY ALLOGENEIC TRANSPLANTATION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS (MMSC) OF LABORATORY ANIMALS | 2022 |
|
RU2802673C1 |
